Coya Therapeutics Files Q1 2025 10-Q
Ticker: COYA · Form: 10-Q · Filed: May 13, 2025 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, warrants
TL;DR
Coya Therapeutics filed its Q1 2025 10-Q. Financials look steady, warrants are a focus.
AI Summary
Coya Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations, including details on common stock warrants and fair value measurements. Specific financial data points such as retained earnings and general and administrative expenses for the first quarter of 2024 were also disclosed.
Why It Matters
This filing provides investors with an update on Coya Therapeutics' financial performance and operational status for the first quarter of 2025, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: medium — The filing contains standard financial disclosures for a public company, but the nature of the pharmaceutical industry and early-stage development can introduce inherent risks.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the latest financial snapshot provided.)
- 2024-03-31 — Prior Year Quarter End (Provides a comparative point for financial performance.)
- 2024-01-01 — Start of Q1 2024 (Marks the beginning of the period for which expenses are detailed.)
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Filer of the 10-Q
- 2025-03-31 (date) — End of reporting period
- 2024-01-01 (date) — Start of reporting period for Q1 2024 expenses
- 2024-03-31 (date) — End of Q1 2024 expenses and retained earnings date
- Arscience Biotherapeutics Inc (company) — Mentioned in relation to a product
FAQ
What is the primary focus of Coya Therapeutics' business as indicated by the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to Pharmaceutical Preparations.
What specific financial reporting period does this 10-Q cover?
This 10-Q filing covers the period ending March 31, 2025.
What types of financial instruments are mentioned in relation to Coya Therapeutics' filings?
The filing mentions Common Stock Warrants and Employee Stock Options.
What is the business address of Coya Therapeutics, Inc.?
The business address is 12645 Memorial Dr., Suite F1 #305, Houston, TX 77024.
What are some of the expense categories mentioned for the first quarter of 2024?
The filing mentions General and Administrative Expense for the period of January 1, 2024, to March 31, 2024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Coya Therapeutics, Inc. (COYA).